financetom
Business
financetom
/
Business
/
Update On OceanaGold; National Bank Sees Waihi North and Macraes Update as "Positive", But Shares Lower
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update On OceanaGold; National Bank Sees Waihi North and Macraes Update as "Positive", But Shares Lower
Oct 7, 2024 7:23 AM

09:49 AM EDT, 10/07/2024 (MT Newswires) -- OceanaGold ( OCANF ) was at last look down 1.6% in early Monday trade after it over the weekend said that its Waihi and Macraes mines have been included on the list of proposed projects to get fast-track approval by New Zealand government for regionally and nationally significant infrastructure and development projects.

A statement noted the Waihi North Project includes the highly prospective Wharekirauponga (WKP) proposed underground mine, as well as the Macraes Phase 4 Project, involving a mine extension permit.

The Fast-track Approvals Bill is expected to be passed into law later this year, allowing listed projects to apply directly to a Government-appointed expert panel for final decision, OceanaGold ( OCANF ) said.

"Expediting the permitting of our projects will preserve the jobs of 1,000 employees we have in New Zealand, provides new jobs and will deliver wider economic benefits for the local communities and the country," said OceanaGold ( OCANF ) President and CEO Gerard Bond.

National Bank, which has an Outperform rating and C$55 Target on OGC, said the impact of the should be "positive."

The bank said OceanaGold ( OCANF ) remains its 'Top Pick' in the Intermediate precious metal space for its significant near-term production and EBITDA growth due to the completion of the Haile U/G ramp-up earlier this year. National derived its C$5.00 target price for OceanaGold ( OCANF ) from a 100% weighted 3.25x NTM EV/EBITDA target multiple, which implies a 1.05x P/NAV multiple. As of Friday's close, OceanaGold ( OCANF ) was trading at 3.4x and 2.8x National's 2024 and 2025 estimates on an EV/EBITDA basis and 0.82x NAV on a cash-adjusted basis.

Price: 3.69, Change: -0.07, Percent Change: -1.86

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Velan Q1 sales rise 18.6%, raises dividend
Velan Q1 sales rise 18.6%, raises dividend
Jul 10, 2025
Overview * Velan's ( VLNSF ) fiscal Q1 sales rise 18.6% to $72.2 mln, boosting gross profit margin * Reports net income from continuing operations of $17.8 mln compared to loss of $2.2 mln a year earlier * Increases quarterly dividend to C$0.10 per share from C$0.03 Outlook * Velan ( VLNSF ) expects to deliver solid performance despite tariff...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Roku Insider Sold Shares Worth $2,241,032, According to a Recent SEC Filing
Roku Insider Sold Shares Worth $2,241,032, According to a Recent SEC Filing
Jul 10, 2025
06:00 PM EDT, 07/10/2025 (MT Newswires) -- Anthony J. Wood, 10% Owner, Director, CEO and Chairman of Board of Directors, on July 10, 2025, sold 25,000 shares in Roku ( ROKU ) for $2,241,032. Following the Form 4 filing with the SEC, Wood has control over a total of 503,034 Class A common shares of the company, with 11,953 shares...
Delaware Supreme Court sides with Zantac drugmakers over cancer evidence
Delaware Supreme Court sides with Zantac drugmakers over cancer evidence
Jul 10, 2025
* Patients allege that heartburn drug caused their cancer * Court says expert opinions not backed by reliable science * FDA asked in 2020 that Zantac be pulled from market * Lawyer for patients had no immediate comment (Adds details from decision, attempts to obtain comment, case citation, byline) By Jonathan Stempel July 10 (Reuters) - Delaware's highest court ruled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved